- Home
- LIMN vs OPY Comparison
LIMN vs OPY Comparison
Compare LIMN & OPY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIMN
- OPY
- Stock Information
- Founded
- LIMN 2018
- OPY 1881
- Country
- LIMN United States
- OPY United States
- Employees
- LIMN N/A
- OPY N/A
- Industry
- LIMN
- OPY Investment Bankers/Brokers/Service
- Sector
- LIMN
- OPY Finance
- Exchange
- LIMN NYSE
- OPY Nasdaq
- Market Cap
- LIMN 623.8M
- OPY 696.7M
- IPO Year
- LIMN N/A
- OPY N/A
- Fundamental
- Price
- LIMN $6.65
- OPY $66.21
- Analyst Decision
- LIMN
- OPY
- Analyst Count
- LIMN 0
- OPY 0
- Target Price
- LIMN N/A
- OPY N/A
- AVG Volume (30 Days)
- LIMN 510.5K
- OPY 74.3K
- Earning Date
- LIMN 01-01-0001
- OPY 07-25-2025
- Dividend Yield
- LIMN N/A
- OPY 1.09%
- EPS Growth
- LIMN N/A
- OPY 84.56
- EPS
- LIMN N/A
- OPY 6.74
- Revenue
- LIMN N/A
- OPY $1,358,354,000.00
- Revenue This Year
- LIMN N/A
- OPY N/A
- Revenue Next Year
- LIMN N/A
- OPY N/A
- P/E Ratio
- LIMN N/A
- OPY $9.93
- Revenue Growth
- LIMN N/A
- OPY 12.80
- 52 Week Low
- LIMN $4.40
- OPY $47.39
- 52 Week High
- LIMN $33.66
- OPY $73.12
- Technical
- Relative Strength Index (RSI)
- LIMN N/A
- OPY 56.53
- Support Level
- LIMN N/A
- OPY $66.34
- Resistance Level
- LIMN N/A
- OPY $67.58
- Average True Range (ATR)
- LIMN 0.00
- OPY 1.62
- MACD
- LIMN 0.00
- OPY 0.02
- Stochastic Oscillator
- LIMN 0.00
- OPY 66.02
About LIMN LIMINATUS PHARMA INC
Liminatus Pharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing cancer therapies and treatments. The GCC Vaccine of the company is in Phase II of clinical trials designed for immune behavior towards colorectal, pancreatic, gastric, and esophageal cancers that express Guanylyl Cyclase C.
About OPY Oppenheimer Holdings Inc. (DE)
Oppenheimer Holdings Inc conducts activities in the securities industry. The company is involved in retail securities brokerage, investment banking (both corporate and public finance), institutional sales and trading, market-making, research, trust services, and investment advisory and asset management services. The company has two segments: Wealth Management, and Capital Markets. IT generates maximum revenue from Wealth Management Segment which includes commissions and fee income earned on assets under management (AUM), net interest earnings on client margin loans and cash balances, fees from money market funds, custodian fees and other activities. The company generates the majority of its revenue from the Americas, with the rest from Europe, the Middle East, and Asia.